TrialLeukemia & lymphoma2015

A phase II study of the combination of rituximab and granulocyte macrophage colony stimulating factor as treatment of patients with chronic lymphocytic leukemia.

Paolo Strati et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.